 | |
| Clinical data | |
|---|---|
| Other names | LG-121071; LGD-121071 |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H15F3N2O |
| Molar mass | 296.293 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
LG121071 (orLGD-121071) is aselective androgen receptor modulator (SARM) developed byLigand Pharmaceuticals that was first described in 1999 and was the firstorallyactivenonsteroidalandrogen to be discovered.[1][2] It is atricyclicquinolone derivative, structurally distinct from other nonsteroidal AR agonists likeandarine andenobosarm (ostarine).[2] The drug acts as a high-affinityfull agonist of theandrogen receptor (AR) (Ki = 17 nM),[2] with apotency andefficacy that is said to be equivalent to that ofdihydrotestosterone (DHT).[3] Unlike testosterone, but similarly to DHT, LG121071 and other nonsteroidal androgens cannot be potentiated by5α-reductase in androgenic tissues (noraromatized intoestrogenicmetabolites), and for this reason, show tissue-selective androgenic effects.[4] In accordance, they are said to possess fullanabolic activity with reducedandrogenic activity, similarly toanabolic-androgenic steroids.[5]
Thein vitrometabolism of LG121071 has been characterized in anticipation of its possible use as adoping agent.[5][6]
